Anti-cd20 antibodies and fusion proteins therof and methods of use
AssigneeImmunomedics, Inc.
InventorsHans HANSEN, Zhengxing QU, David M. GOLDENBERG
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.
Claims26
A method of treating an autoimmune disease in a subject, wherein said autoimmune disease is mediated by B-cells, comprising administering to said subject a therapeutically effective amount of a chimeric, humanized or human monoclonal antibody that binds to CD20, said antibody having a light chain variable region CDR1 comprising a sequence RASSSVSYIH (SEQ ID NO:1);
- CDR2 comprising a sequence ATSNLAS (SEQ ID NO:4);
- and CDR3 comprising a sequence QQWTSNPPT (SEQ ID NO:5);
- and said antibody having a heavy chain variable region CDR1 comprising a sequence SYNMH (SEQ ID NO:8);
- CDR2 comprising a sequence AIYPGNGDTSYNQKFKG (SEQ ID NO:9);
- and CDR3 comprising a sequence STYYGGDWYFDV (SEQ ID NO:10) or a sequence VVYYSNSYWYFDV (SEQ ID NO:
- 13).
Dependencies are inferred from the claim text.